Target and Genmab Show Strength as S&P 500 Falls — JournalArta Global
Target (TGT) and Genmab (GEN) showed relative strength against the S&P 500's record weekly loss. Target raised its earnings forecast to $10.65–$11.40, while Genmab reported positive cancer trial results. Other stocks mentioned include Cheesecake Factory (CAKE), Netskope (NK), and Welltower (WELL).
How this was made

The 30-second read
Why it matters
The highlighted companies each delivered distinct catalysts—Target's earnings outlook, Genmab's trial data, and Welltower's fund‑flow growth—offering traders sector‑specific opportunities.
Market read
In a weak broad market, these stocks showed resilience, making them potential short‑term plays for traders seeking upside or defensive positions.
What to watch
Potential supply‑chain constraints for Target's Fun 101 category and regulatory review timelines for Genmab's drugs.
Background
The S&P 500 posted its worst weekly point loss on record, prompting a relative‑strength scan that highlighted five stocks across diverse sectors.
Ticker impact
Target raised its full‑year EPS forecast to $10.65‑$11.40, prompting a 2.7% weekly share rise.
upward pressure as investors price in higher earnings expectations
Guidance lifts earnings multiples; analysts already note strong comparable‑store growth.
Genmab reported positive cancer‑trial data, including a 50% death‑risk reduction for head‑and‑neck patients, after a 60% October surge.
potential short‑term pressure as market digests trial data and prior rally
Trial data is positive but the stock already ran up sharply, leading to modest pull‑back.
Welltower posted 25% growth in normalized funds from operations and 38% revenue growth in Q3, noting $21 bn of investments for the year.
upward bias as investors value higher NOI growth
Robust fund‑flow growth and rent‑increase driven earnings support a positive outlook.
Market effects
Retail earnings uplift may lift consumer‑discretionary; biotech trial success adds optimism to oncology pipelines.
U.S. retail and REITs benefit; European biotech gains attention from trial data.
Guidance raise and trial results contribute to broader market rotation toward growth and health‑care themes.
Counterpoint
Target's guidance may be overly optimistic given inventory pressures; Genmab's trial data may not translate to commercial success yet.
Key entities
- RetailerTarget
U.S. big‑box retailer with updated earnings guidance.
- BiotechGenmab
Danish oncology company reporting positive trial outcomes.
- REITWelltower
Senior‑housing REIT with strong Q3 fund‑flow growth.



